{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:38:36Z","timestamp":1756384716864},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T00:00:00Z","timestamp":1527897600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s42000-018-0036-2","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T04:35:55Z","timestamp":1527914155000},"page":"423-426","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Myasthenia gravis imitating pituitary apoplexy in macroprolactinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Matteo","family":"Zoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Guaraldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Faustini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Mazzatenta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,2]]},"reference":[{"issue":"1","key":"36_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ecl.2014.11.003","volume":"44","author":"A Glezer","year":"2015","unstructured":"Glezer A, Bronstein MD (2015) Prolactinomas. Endocrinol Metab Clin N Am 44(1):71\u201378","journal-title":"Endocrinol Metab Clin N Am"},{"key":"36_CR2","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1365-2265.2008.03364.x","volume":"70","author":"G Raverot","year":"2009","unstructured":"Raverot G, Jacob M, Jouanneau E et al (2009) Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clin Endocrinol 70:588\u2013592","journal-title":"Clin Endocrinol"},{"key":"36_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1046\/j.1365-2265.2000.00901.x","volume":"52","author":"KS Leong","year":"2000","unstructured":"Leong KS, Foy PM, Swift AC, Atkin SL, Hadden DR, MacFarlane IA (2000) CSF rhinorroea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol 52:43\u201349","journal-title":"Clin Endocrinol"},{"issue":"12","key":"36_CR4","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.jocn.2013.02.027","volume":"20","author":"E Chng","year":"2013","unstructured":"Chng E, Dalan R (2013) Pituitary apoplexy associated with cabergoline therapy. J Clin Neurosci 20(12):1637\u20131643","journal-title":"J Clin Neurosci"},{"key":"36_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.wneu.2017.06.117","volume":"106","author":"M Zoli","year":"2017","unstructured":"Zoli M, Milanese L, Faustini-Fustini M et al (2017) Endoscopic endonasal surgery for pituitary apoplexy: evidence on a 75-case series from a tertiary care center. World Neurosurg 106:331\u2013338","journal-title":"World Neurosurg"},{"issue":"26","key":"36_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581","journal-title":"N Engl J Med"},{"issue":"3","key":"36_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1080\/14737175.2017.1241144","volume":"17","author":"JI Lee","year":"2017","unstructured":"Lee JI, Jander S (2017) Myasthenia gravis: recent advances in immunopathology and therapy. Expert Rev Neurother 17(3):287\u2013299","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"36_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1365-2265.2010.03913.x","volume":"74","author":"S Rajasekaran","year":"2011","unstructured":"Rajasekaran S, Vanderpump M, Baldeweg S et al (2011) UK guidelines for the management of pituitary apoplexy. Clin Endocrinol 74(1):9\u201320","journal-title":"Clin Endocrinol"},{"issue":"5","key":"36_CR9","doi-asserted-by":"publisher","first-page":"G12","DOI":"10.1530\/EC-16-0057","volume":"5","author":"SE Baldeweg","year":"2016","unstructured":"Baldeweg SE, Vanderpump M, Drake W et al (2016) Society for endocrinology endocrine emergency guidance: emergency management of pituitary apoplexy in adult patients. Endocr Connect 5(5):G12\u2013G15","journal-title":"Endocr Connect"},{"key":"36_CR10","first-page":"310","volume":"6","author":"DFW Cahill","year":"1980","unstructured":"Cahill DFW, Sellman MS, Salcman M (1980) Prolactin-secreting adenoma in a myasthenic patient. Neurosurg 6:310\u2013313","journal-title":"Neurosurg"},{"key":"36_CR11","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1600-0404.2006.00664.x","volume":"114","author":"N Tsinzerling","year":"2006","unstructured":"Tsinzerling N, Pirskanen R, Matell G et al (2006) Raised prolactin levels in myasthenia gravis : two case reports and a study of two patient populations. Acta Neurol Scand 114:346\u2013349","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"36_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12020-013-9991-1","volume":"45","author":"SM Harris","year":"2014","unstructured":"Harris SM, Leong HM, Chowdhury R, Ellis C, Brennan J, Scobie IN (2014) Concomitant myasthenia gravis and macroprolactinoma: the immunomodulatory role of prolactin and its potential therapeutic use. Endocrine 45(1):9\u201314","journal-title":"Endocrine"},{"key":"36_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000452906","volume":"48","author":"W Savino","year":"2017","unstructured":"Savino W (2017) Prolactin: an immunomodulator in health and disease. Front Horm Res 48:69\u201375","journal-title":"Front Horm Res"},{"key":"36_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1210\/rp.57.1.435","volume":"57","author":"LY Yu-Lee","year":"2002","unstructured":"Yu-Lee LY (2002) Prolactin modulation of immune and inflammatory responses. Recent Prog Horm Res 57:435\u2013455","journal-title":"Recent Prog Horm Res"},{"key":"36_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0896-8411(03)00095-7","volume":"21","author":"HJ Garchon","year":"2003","unstructured":"Garchon HJ (2003) Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J Autoimmun 21:105\u2013110","journal-title":"J Autoimmun"},{"key":"36_CR16","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.mehy.2007.06.044","volume":"70","author":"M Yang","year":"2008","unstructured":"Yang M, Huang L, Liu W, Sheng Z, Xie H, Liao E (2008) Prolactin may be a promising therapeutic target for myasthenia gravis: hypothesis and importance. Med Hypoth 70:1017\u20131020","journal-title":"Med Hypoth"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-018-0036-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0036-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0036-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T01:44:53Z","timestamp":1559439893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-018-0036-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,2]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s42000-018-0036-2","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,2]]},"assertion":[{"value":"2 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}